Zhao F-L, Hu G-D, Wang X-F, Zhang X-H, Zhang Y-K, Yu Z-S
Department of Orthopaedics, The Luhe Teaching Hospital of the Capital Medical University, Beijing, China.
J Int Med Res. 2012;40(3):859-66. doi: 10.1177/147323001204000304.
Bone metastasis is a major complication of advanced breast cancer. The present prospective case-control study investigated the involvement of microRNA (miR)-10b in the development of bone metastasis arising from primary breast carcinoma.
Serum miR-10b concentrations were determined by quantitative real-time reverse transcription-polymerase chain reaction in 122 patients with breast cancer, with or without bone metastases, and 59 age-matched healthy control subjects.
Serum miR-10b concentrations were significantly higher in patients with bone metastases than in patients without bone metastases or control subjects. Serum miR-10b had an area under the receiver operating characteristic curve for the presence of bone metastases of 0.769, with 64.8% sensitivity and 69.5% specificity.
These results suggest that serum miR-10b may be a useful biomarker for the identification of bone metastatic breast cancer.
骨转移是晚期乳腺癌的主要并发症。本前瞻性病例对照研究调查了微小RNA（miR）-10b在原发性乳腺癌骨转移发生过程中的作用。
采用定量实时逆转录-聚合酶链反应测定122例有或无骨转移的乳腺癌患者以及59例年龄匹配的健康对照者血清中miR-10b的浓度。
骨转移患者血清miR-10b浓度显著高于无骨转移患者或对照者。血清miR-10b用于检测骨转移的受试者工作特征曲线下面积为0.769，灵敏度为64.8%，特异度为69.5%。
这些结果表明血清miR-10b可能是识别骨转移性乳腺癌的有用生物标志物。
